Season 2, Episode #4 - The Rise of Radiopharmaceuticals, Andrew Lake Wooten
Andrew Lake Wooten, founder of Wooten Consulting and a specialist in isotopes and radiopharmaceuticals, joins the show. With more than a decade of experience across isotope production, radiochemistry, GMP manufacturing, facility development and commercial strategy, Lake has worked across some of the most complex parts of the radiopharmaceutical supply chain. He previously led the development of Orano Med’s Indianapolis manufacturing site and now advises companies across the sector, teaches radiochemistry through Purdue University, and sits on the board of CyGen Alpha Systems. In this episode, we take a step back and explore the rapidly growing world of radiopharmaceuticals from the ground up — how they work, why they’re attracting so much attention in cancer care, and what still needs to happen for the industry to scale. We discuss: What a radiopharmaceutical actually is, and how radioactive isotopes can be used for both imaging and therapy How drug molecules target cancer cells while carrying a radioactive “payload” Why radiopharmaceuticals have the potential to deliver highly targeted cancer treatment The importance of isotope choice — and why the “best” isotope is not always the one that gets used Why supply chain and commercial viability can influence scientific decision-making The race to develop and scale isotopes such as Astatine-211 Why manufacturing and logistics are so different from traditional pharmaceuticals The challenge of working with products that begin decaying from the moment they are created Radiation safety, regulation, GMP manufacturing and the complexity of getting therapies into patients Why Indiana has emerged as one of the world’s major hubs for radiopharmaceutical manufacturing The infrastructure and workforce challenges that could determine how quickly the industry grows How Lake helps companies enter the US market, scale facilities and avoid expensive strategic mistakes His work with the Oncidium Foundation , a patient-focused organisation helping expand awareness and access to radioligand therapies, including coordinating isotope donations for patients in countries where these treatments may otherwise be unavailable A fascinating introduction to one of the fastest-moving areas of oncology, sitting at the intersection of nuclear science, drug development, manufacturing and patient care. https://www.linkedin.com/in/a-lake-wooten/ https://www.linkedin.com/in/charlie-webb-a5605768/ https://www.linkedin.com/in/sumair-gill-086a151a1/